Answers are grounded in this paper and cite their sources.
This review addresses the relationship between obesity and disorders of gut-brain interaction, as well as gastrointestinal adverse events arising during pharmacotherapy of obesity with incretin mimetics (semaglutide, tirzepatide). According to population-based studies, obesity is associated with an increased prevalence of disorders of gut-brain interaction, and the risk rises as body mass index increases. The high incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) during therapy with incretin receptor agonists frequently leads to dose reduction or treatment discontinuation. The review discusses the concept of „motility support“ for incretin-based pharmacotherapy of obesity using trimebutine, a motility regulator with a modulating mode of action. The rationale draws on the results of randomized clinical trials and meta-analyses. Thus, personalized correction of gastrointestinal motility disorders may improve treatment tolerability and adherence; further investigation of this strategy will help define its place in clinical practice more precisely.
No takes yet. Share an insight, caveat, or question.
Суплотова et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: